title: Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study.
abstract: Factor VII Activating Protease (FSAP) activates factor VII (FVII) as well as pro-urokinase (uPA). Our goal was to evaluate the relation between plasma levels of FSAP and clinical instability in atrial fibrillation (AF) and possible effects of oral omega-3 fatty acids (FA) supplements. 101 patients with persistent AF were analyzed in the OMEGA-AF Study. Plasma FSAP levels were measured at baseline and after 12 weeks of treatment with omega-3 FA. The median FSAP antigen concentration, in contrast to FSAP activity, was higher in patients with persistent AF. The maintenance of SR after successful cardioversion (CV) did not lead to a normalization of FSAP concentration. Supplementation with omega-3 FA but not placebo significantly reduced elevated FSAP concentration. Furthermore, elevated FSAP levels did not indicate a significantly increased risk of recurrence of AF after electrical CV or cardiovascular clinical events during 1 year of follow-up. Plasma FSAP concentration was increased in patients with AF and may be involved in the pathogenesis of this condition. The possible effects of omega-3 FA on clinical AF potential could be linked with modulation of circulating FSAP levels.
authors.affiliation: Internal Medicine I/Cardiology and Angiology, University Hospital of Giessen and Marburg, Klinikstr. 36, 35392, Giessen, Germany, mariana.parahuleva@innere.med.uni-giessen.de.
authors.forename: Mariana S
authors.initials: MS
authors.lastname: Parahuleva
authors.forename: Sandip
authors.initials: S
authors.lastname: Kanse
authors.forename: Hans
authors.initials: H
authors.lastname: Hölschermann
authors.forename: Kirila
authors.initials: K
authors.lastname: Zheleva
authors.forename: Daniel
authors.initials: D
authors.lastname: Zandt
authors.forename: Michael
authors.initials: M
authors.lastname: Worsch
authors.forename: Behnoush
authors.initials: B
authors.lastname: Parviz
authors.forename: Norbert
authors.initials: N
authors.lastname: Güttler
authors.forename: Harald
authors.initials: H
authors.lastname: Tillmanns
authors.forename: Andreas
authors.initials: A
authors.lastname: Böning
authors.forename: Ali
authors.initials: A
authors.lastname: Erdogan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000097:blood* / Q000178:diet therapy*; D019587:Dietary Supplements; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012697:Serine Endopeptidases / Q000097:blood*
chemical_list: D015525:Fatty Acids, Omega-3; C433550:HABP2 protein, human; D012697:Serine Endopeptidases